Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of
next-generation biopharmaceuticalsSupporting R optimization of next-generation biopharmaceuticals with digital technology and drug discovery platform
TOKYO, Apr 7, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) and Axcelead, Inc. today announced that they have agreed
on a comprehensive collaborative partnership to develop solutions contributing on more efficient creation of
next-generation biopharmaceuticals with digital technology and drug discovery platform. Hitachi has also made investment
to Drug Discovery Gateway Fund ("DDG Fund") managed by Whiz Partners Inc. (President: Atsushi Matsumura, "Whiz").
Axcelead is the flagship portfolio company of DDG Fund.
With continuous progress of life science, practical applications of next-generation biopharmaceuticals with new
therapeutics modalities(1) demonstrating better balance of efficacy and side-effect, such as genes-, cell-, and mRNA(2)-
therapeutics, have been recognized. Those new drug discovery modalities are also contributing to the speedy and variety
development of vaccines and therapeutics for COVID-19.
On the other hand, next-generation biopharmaceuticals are more expensive to develop and manufacture than
low-molecular-weight pharmaceuticals, and due to their nature, the product stability and effective period and product
life are shorter, and it would be better to develop and manufacture products with small quantity and high variety.
Manufacturing costs and risks tend to be high.
Through this collaboration, Hitachi and Axcelead will develop solutions that support the more efficient creation of
next-generation biopharmaceuticals with digital technology and drug discovery platforms, and also support entities that
participate in this field. In addition, the both companies will jointly promote the development of specialized human
resources who are familiar with the development and manufacturing of next-generation biopharmaceuticals.
Hitachi, with over 100 years deep experience in manufacturing industry, has provided many companies with variety of
solutions utilizing Lumada, which accelerates digital innovation by combining OT, IT, and products. In the field of
regenerative medicine, Hitachi provides automated cell culture equipment for iPS cells, cell processing facilities,
manufacturing execution systems, biosafety cabinets, etc., to pharmaceutical companies and research institutes according
to customer needs.
Axcelead is a drug desicovery platform company group, having its core company, Axcelead Drug Discovery Partners, Inc.
("ADDP"), which took over the drug discovery platform business of Takeda Pharmaceutical Co., Ltd. ("Takeda") and started
Japan's first integrated drug discovery solution provider business in 2017. With the investments from DDG Fund, Axcelead
sees the horizontal division of labor of pharmaceutical companies as a business opportunity, and has desided to entered
the mRNA therapeutics CDMO(3) busienss, DDS(4) technology development business, and drug development business. Axcelead
by themselves are going to build ecosystem in this field.
Hitachi and Axcelead aim to contribute to improving QoL (Quality of Life) for human through medical innovation with
(1) Therapeutics modality: A general term for the mechanism of action, materials, and treatment methods of drugs.
(2) mRNA: Abbreviation for messenger RNA, a blueprint for making proteins. It is made from DNA in the cell's nucleus and
is degraded shortly after it is used to make proteins.
(3) CDMO (Contract Development Manufacturing Organization): A pharmaceutical contract manufacturing and development
organization that is entrusted by a customer and makes into practice on behalf of, which are not only pharmaceutical
manufacturing but also development.
(4) DDS (Drug Delivery System): A technology aimed at maximizing the effects of drugs and minimizing side effects by
controlling the distribution of drugs in the body.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focused on its Social Innovation Business that combines
information technology (IT), operational technology (OT) and products. The company's consolidated revenues for fiscal
year 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 billion), and it employed approximately 301,000
people worldwide. Hitachi drives digital innovation across five sectors - Mobility, Smart Life, Industry, Energy and IT
- through Lumada, Hitachi's advanced digital solutions, services, and technologies for turning data into insights to
drive digital innovation. Its purpose is to deliver solutions that increase social, environmental and economic value for
its customers. For more information on Hitachi, please visit the company's website at https://www.hitachi.com
About Axcelead, Inc.
Axcelead is a group of companies that develops a drug discovery platform business centered on ADDP, Japan's first
integrated drug discovery solution provider, which took over Takeda's drug discovery platform business in 2017.
Axcelead, is the flagship portfolio company of DDG Fund, which was jointly established by Whiz and Takeda in 2018, with
the aim of promoting the drug discovery ecosystem in Japan, and will make various contributions to healthcare broadly